(SPNS) Sapiens International - Ratings and Ratios
Exchange: NASDAQ •
Country: Israel •
Currency: USD •
Type: Common Stock •
ISIN: KYG7T16G1039
Insurance, Software, Platform, Consultancy, Reinsurance
Dividends
| Dividend Yield | 1.52% |
| Yield on Cost 5y | 2.58% |
| Yield CAGR 5y | 42.05% |
| Payout Consistency | 78.3% |
| Payout Ratio | 45.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 58.8% |
| Value at Risk 5%th | 64.6% |
| Relative Tail Risk | -33.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.10 |
| Alpha | 50.74 |
| CAGR/Max DD | 0.90 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.370 |
| Beta | 0.752 |
| Beta Downside | 0.671 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.67% |
| Mean DD | 11.96% |
| Median DD | 7.93% |
Description: SPNS Sapiens International November 13, 2025
Sapiens International Corp. (NASDAQ: SPNS) develops and sells cloud-native software for insurers across property-and-casualty, life & pensions, and reinsurance markets in North America, Europe and beyond. Its flagship offerings include IDIT Suite (AI-driven end-to-end processing), Digital Suite (customer-facing engagement), Core Suite (policy administration), CustomerConnect/AgentConnect portals, and ReinsuranceMaster for automated reinsurance workflow.
In FY 2023 the company generated $618 million in revenue, with subscription-based ARR expanding at roughly 20% YoY and subscription revenue now representing about 70% of total sales-metrics that underscore the shift toward recurring-revenue models in insurance tech. Growth is being propelled by macro-level drivers such as accelerated digital transformation in the insurance sector (projected 13% CAGR for cloud adoption through 2029) and heightened regulatory pressure for real-time data analytics, both of which favor AI-enabled platforms like Sapiens.
For a deeper, data-driven valuation perspective, you may find ValueRay’s analyst platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (64.3m TTM) > 0 and > 6% of Revenue (6% = 33.9m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA -0.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.19% (prev 32.30%; Δ -17.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 80.0m > Net Income 64.3m (YES >=105%, WARN >=100%) |
| Net Debt (-38.7m) to EBITDA (93.5m) ratio: -0.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.4m) change vs 12m ago 0.22% (target <= -2.0% for YES) |
| Gross Margin 44.30% (prev 43.40%; Δ 0.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 79.09% (prev 78.87%; Δ 0.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 196.1 (EBITDA TTM 93.5m / Interest Expense TTM 395.0k) >= 6 (WARN >= 3) |
Altman Z'' 4.68
| (A) 0.12 = (Total Current Assets 251.8m - Total Current Liabilities 166.0m) / Total Assets 743.7m |
| (B) 0.22 = Retained Earnings (Balance) 160.2m / Total Assets 743.7m |
| (C) 0.11 = EBIT TTM 77.5m / Avg Total Assets 713.5m |
| (D) 2.37 = Book Value of Equity 513.5m / Total Liabilities 216.5m |
| Total Rating: 4.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.71
| 1. Piotroski 7.50pt |
| 2. FCF Yield 3.04% |
| 3. FCF Margin 12.77% |
| 4. Debt/Equity 0.08 |
| 5. Debt/Ebitda -0.41 |
| 6. ROIC - WACC (= 3.43)% |
| 7. RoE 13.18% |
| 8. Rev. Trend 95.46% |
| 9. EPS Trend 79.13% |
What is the price of SPNS shares?
As of December 02, 2025, the stock is trading at USD 43.28 with a total of 260,407 shares traded.
Over the past week, the price has changed by +0.63%, over one month by +0.44%, over three months by +0.89% and over the past year by +61.77%.
Over the past week, the price has changed by +0.63%, over one month by +0.44%, over three months by +0.89% and over the past year by +61.77%.
Is SPNS a buy, sell or hold?
Sapiens International has received a consensus analysts rating of 2.80.
Therefor, it is recommend to hold SPNS.
- Strong Buy: 0
- Buy: 1
- Hold: 2
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the SPNS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.3 | -13.9% |
| Analysts Target Price | 37.3 | -13.9% |
| ValueRay Target Price | 53.6 | 23.9% |
SPNS Fundamental Data Overview November 25, 2025
Market Cap USD = 2.41b (2.41b USD * 1.0 USD.USD)
P/E Trailing = 37.4348
P/E Forward = 29.5858
P/S = 4.2644
P/B = 4.6868
P/EG = 5.9208
Beta = 0.901
Revenue TTM = 564.3m USD
EBIT TTM = 77.5m USD
EBITDA TTM = 93.5m USD
Long Term Debt = 19.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 26.2m USD (from shortTermDebt, last quarter)
Debt = 43.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -38.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.37b USD (2.41b + Debt 43.5m - CCE 82.2m)
Interest Coverage Ratio = 196.1 (Ebit TTM 77.5m / Interest Expense TTM 395.0k)
FCF Yield = 3.04% (FCF TTM 72.1m / Enterprise Value 2.37b)
FCF Margin = 12.77% (FCF TTM 72.1m / Revenue TTM 564.3m)
Net Margin = 11.40% (Net Income TTM 64.3m / Revenue TTM 564.3m)
Gross Margin = 44.30% ((Revenue TTM 564.3m - Cost of Revenue TTM 314.3m) / Revenue TTM)
Gross Margin QoQ = 44.19% (prev 43.71%)
Tobins Q-Ratio = 3.18 (Enterprise Value 2.37b / Total Assets 743.7m)
Interest Expense / Debt = 0.91% (Interest Expense 395.0k / Debt 43.5m)
Taxrate = 20.12% (3.62m / 18.0m)
NOPAT = 61.9m (EBIT 77.5m * (1 - 20.12%))
Current Ratio = 1.52 (Total Current Assets 251.8m / Total Current Liabilities 166.0m)
Debt / Equity = 0.08 (Debt 43.5m / totalStockholderEquity, last quarter 513.5m)
Debt / EBITDA = -0.41 (Net Debt -38.7m / EBITDA 93.5m)
Debt / FCF = -0.54 (Net Debt -38.7m / FCF TTM 72.1m)
Total Stockholder Equity = 488.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.65% (Net Income 64.3m / Total Assets 743.7m)
RoE = 13.18% (Net Income TTM 64.3m / Total Stockholder Equity 488.0m)
RoCE = 15.25% (EBIT 77.5m / Capital Employed (Equity 488.0m + L.T.Debt 19.8m))
RoIC = 12.07% (NOPAT 61.9m / Invested Capital 512.7m)
WACC = 8.64% (E(2.41b)/V(2.45b) * Re(8.78%) + D(43.5m)/V(2.45b) * Rd(0.91%) * (1-Tc(0.20)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF Debug] Terminal Value 76.98% ; FCFE base≈71.6m ; Y1≈78.1m ; Y5≈98.6m
Fair Price DCF = 26.81 (DCF Value 1.50b / Shares Outstanding 55.9m; 5y FCF grow 10.35% → 3.0% )
EPS Correlation: 79.13 | EPS CAGR: 3.19% | SUE: 0.89 | # QB: 4
Revenue Correlation: 95.46 | Revenue CAGR: 6.75% | SUE: 2.85 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.55 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+6.7% | Growth Revenue=+6.7%
P/E Trailing = 37.4348
P/E Forward = 29.5858
P/S = 4.2644
P/B = 4.6868
P/EG = 5.9208
Beta = 0.901
Revenue TTM = 564.3m USD
EBIT TTM = 77.5m USD
EBITDA TTM = 93.5m USD
Long Term Debt = 19.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 26.2m USD (from shortTermDebt, last quarter)
Debt = 43.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -38.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.37b USD (2.41b + Debt 43.5m - CCE 82.2m)
Interest Coverage Ratio = 196.1 (Ebit TTM 77.5m / Interest Expense TTM 395.0k)
FCF Yield = 3.04% (FCF TTM 72.1m / Enterprise Value 2.37b)
FCF Margin = 12.77% (FCF TTM 72.1m / Revenue TTM 564.3m)
Net Margin = 11.40% (Net Income TTM 64.3m / Revenue TTM 564.3m)
Gross Margin = 44.30% ((Revenue TTM 564.3m - Cost of Revenue TTM 314.3m) / Revenue TTM)
Gross Margin QoQ = 44.19% (prev 43.71%)
Tobins Q-Ratio = 3.18 (Enterprise Value 2.37b / Total Assets 743.7m)
Interest Expense / Debt = 0.91% (Interest Expense 395.0k / Debt 43.5m)
Taxrate = 20.12% (3.62m / 18.0m)
NOPAT = 61.9m (EBIT 77.5m * (1 - 20.12%))
Current Ratio = 1.52 (Total Current Assets 251.8m / Total Current Liabilities 166.0m)
Debt / Equity = 0.08 (Debt 43.5m / totalStockholderEquity, last quarter 513.5m)
Debt / EBITDA = -0.41 (Net Debt -38.7m / EBITDA 93.5m)
Debt / FCF = -0.54 (Net Debt -38.7m / FCF TTM 72.1m)
Total Stockholder Equity = 488.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.65% (Net Income 64.3m / Total Assets 743.7m)
RoE = 13.18% (Net Income TTM 64.3m / Total Stockholder Equity 488.0m)
RoCE = 15.25% (EBIT 77.5m / Capital Employed (Equity 488.0m + L.T.Debt 19.8m))
RoIC = 12.07% (NOPAT 61.9m / Invested Capital 512.7m)
WACC = 8.64% (E(2.41b)/V(2.45b) * Re(8.78%) + D(43.5m)/V(2.45b) * Rd(0.91%) * (1-Tc(0.20)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.47%
[DCF Debug] Terminal Value 76.98% ; FCFE base≈71.6m ; Y1≈78.1m ; Y5≈98.6m
Fair Price DCF = 26.81 (DCF Value 1.50b / Shares Outstanding 55.9m; 5y FCF grow 10.35% → 3.0% )
EPS Correlation: 79.13 | EPS CAGR: 3.19% | SUE: 0.89 | # QB: 4
Revenue Correlation: 95.46 | Revenue CAGR: 6.75% | SUE: 2.85 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.39 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.55 | Chg30d=+0.010 | Revisions Net=+1 | Growth EPS=+6.7% | Growth Revenue=+6.7%
Additional Sources for SPNS Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle